Re: FROM AMERICAN HOME PRODUCTS/WYETH

[Guest guest]

"...affects people 50 years or older." Does that mean all you young folks don't really have fibrosi? Or the counters just don't count you. Jack79/IPF - UIP/dx06/05 Maine

FROM AMERICAN HOME PRODUCTS/WYETH

Enbrel is in Phase II clinical development for the treatment of asthma as well as for the treatment of idiopathic pulmonary fibrosis.According to Datamonitor Plc. analysts, Enbrel is among several novel antifibrotic agents in clinical trials that offer new hope for major advances in the treatment of idiopathic pulmonary fibrosis by inhibiting the processes that lead to end-stage fibrosis. Idiopathic pulmonary fibrosis is a progressive and lethal disease of elderly patients for which current therapy is minimally effective.To date, very few multicenter trials have been conducted in idiopathic pulmonary fibrosis. Datamonitor analysts estimate, however, that the promising antifibrotic drugs in Phase II/III clinical trials could potentially bring relief to more than 200,000 sufferers and will create a new market estimated to be worth more than $2 billion annually.Idiopathic pulmonary

fibrosis is a disease of unknown cause that affects people 50 years old and older. A typical symptom cluster includes shortness of breath, a chronic dry hacking cough, and chest discomfort. Shortness of breath is usually the most prominent and disabling symptom, although the cough may have a greater impact on a patient's daily life in terms of decreased socialization.The pathology of the disease is poorly understood, although current thinking suggests that the disease is a disorder of wound healing, in which progressive fibrosis gradually interferes with a persons ability to breathe. Novel antifibrotic agents in clinical trials, such as interferon-gamma 1b, pirfenidone, bosentan, and etanercept, which inhibit the process of fibrosis, may prevent the fatal outcome common in idiopathic pulmonary fibrosis patients.There are estimated to be about 220,000 people in the United States, Europe, and

Japan that are affected by idiopathic pulmonary fibrosis, with about 90,000 of these patients in the United States. These figures are comparable to the prevalence of diseases such as chronic myeloid leukemia. As a consequence of misdiagnosis and late presentation, however, the actual number of diagnosed patients is significantly lower.The prevalence of idiopathic pulmonary fibrosis is expected to increase drastically during the next 10 years due to the aging of the population combined with improvements in diagnosis, according to Shaun Falkingbridge, respiratory senior analyst, Datamonitor (datamonitor. com)."Patients have a five-year survival rate of 20%; lower than many neoplastic diseases, including non-Hodgkin' s lymphoma, colorectal cancer, prostate cancer, and breast cancer, although to date very few multicenter trials have been conducted in idiopathic pulmonary fibrosis compared

with diseases with a similar mortality," Mr. Falkingbridge says. "Enbrel has recently completed Phase II clinical trials for idiopathic pulmonary fibrosis and is expected to reach the market in 2009."MARY LOU

[Guest guest]

Jack, I think it just is further proof that they still just don't understand what is going on with this disease... Love and Prayers, Peggy   IPF  2004,  Florida"Worry looks around, Sorry looks back,  Faith looks up."

[Guest guest]

We're rare creatures Jack and we knock out the statistics too much so we're not counted!

However I would love to find out that I don't really have it and am just some sort of super hypocondriac instead!

Love Ze xx>> "...affects people 50 years or older." Does that mean all you young folks don't really have fibrosi? Or the counters just don't count you. > Jack> 79/IPF - UIP/dx06/05 Maine> > > > FROM AMERICAN HOME PRODUCTS/WYETH> > > Enbrel is in Phase II clinical development for the treatment of > asthma as well as for the treatment of idiopathic pulmonary fibrosis.> > According to Datamonitor Plc. analysts, Enbrel is among several novel > antifibrotic agents in clinical trials that offer new hope for major > advances in the treatment of idiopathic pulmonary fibrosis by > inhibiting the processes that lead to end-stage fibrosis. Idiopathic > pulmonary fibrosis is a progressive and lethal disease of elderly > patients for which current therapy is minimally effective.> > To date, very few multicenter trials have been conducted in > idiopathic pulmonary fibrosis. Datamonitor analysts estimate, > however, that the promising antifibrotic drugs in Phase II/III > clinical trials could potentially bring relief to more than 200,000 > sufferers and will create a new market estimated to be worth more > than $2 billion annually.> > Idiopathic pulmonary fibrosis is a disease of unknown cause that > affects people 50 years old and older. A typical symptom cluster > includes shortness of breath, a chronic dry hacking cough, and chest > discomfort. Shortness of breath is usually the most prominent and > disabling symptom, although the cough may have a greater impact on a > patient's daily life in terms of decreased socialization.> > The pathology of the disease is poorly understood, although current > thinking suggests that the disease is a disorder of wound healing, in > which progressive fibrosis gradually interferes with a persons > ability to breathe. Novel antifibrotic agents in clinical trials, > such as interferon-gamma 1b, pirfenidone, bosentan, and etanercept, > which inhibit the process of fibrosis, may prevent the fatal outcome > common in idiopathic pulmonary fibrosis patients.> > There are estimated to be about 220,000 people in the United States, > Europe, and Japan that are affected by idiopathic pulmonary fibrosis, > with about 90,000 of these patients in the United States. These > figures are comparable to the prevalence of diseases such as chronic > myeloid leukemia. As a consequence of misdiagnosis and late > presentation, however, the actual number of diagnosed patients is > significantly lower.> > The prevalence of idiopathic pulmonary fibrosis is expected to > increase drastically during the next 10 years due to the aging of the > population combined with improvements in diagnosis, according to > Shaun Falkingbridge, respiratory senior analyst, Datamonitor > (datamonitor. com).> > "Patients have a five-year survival rate of 20%; lower than many > neoplastic diseases, including non-Hodgkin' s lymphoma, colorectal > cancer, prostate cancer, and breast cancer, although to date very few > multicenter trials have been conducted in idiopathic pulmonary > fibrosis compared with diseases with a similar mortality," Mr. > Falkingbridge says. "Enbrel has recently completed Phase II clinical > trials for idiopathic pulmonary fibrosis and is expected to reach the > market in 2009."> > MARY LOU>